Proinsulin

Introduction

Background

Proinsulin is a precursor protein that is synthesized and processed within the beta cells of the pancreatic islets of Langerhans. Its discovery in the 1960s was a pivotal moment in understanding the complex biosynthesis of insulin, a hormone critical for regulating blood glucose levels. This finding revolutionized the understanding of diabetes and its underlying mechanisms, moving beyond simply recognizing insulin’s role to detailing its origins.

Biological Basis

Proinsulin is encoded by the_INS_gene and is the immediate precursor to mature insulin. Structurally, it consists of three distinct polypeptide chains: an A-chain, a B-chain, and a connecting C-peptide. Following its synthesis, proinsulin undergoes a series of enzymatic cleavages within the beta cells. Specific proteases remove the C-peptide, leaving behind the mature, biologically active insulin molecule (composed of the A and B chains linked by disulfide bonds) and free C-peptide. While proinsulin itself possesses some intrinsic biological activity, it is significantly less potent than mature insulin in stimulating glucose uptake. The primary function of proinsulin is to serve as a stable, single-chain molecule that facilitates the correct folding and disulfide bond formation necessary for the production of functional insulin. Both insulin and C-peptide are then co-secreted into the bloodstream in equimolar amounts in response to elevated blood glucose.

Clinical Relevance

Measuring proinsulin levels can provide valuable insights into beta-cell function and insulin processing efficiency. Elevated circulating proinsulin levels, particularly in relation to insulin, often indicate impaired beta-cell function, which can precede the development of type 2 diabetes. High proinsulin levels are also associated with an increased risk of cardiovascular disease, even in individuals without overt diabetes. Genetic variations within the_INS_gene or genes involved in the proteolytic cleavage and maturation of proinsulin can influence its production, processing, and secretion, thereby affecting an individual’s predisposition to metabolic disorders. As a biomarker, proinsulin helps in assessing insulin resistance, predicting diabetes risk, and monitoring disease progression.

Social Importance

The understanding of proinsulin’s role in insulin synthesis and its clinical implications has significant social importance. It contributes directly to improved diagnostic tools and therapeutic strategies for diabetes, a global health challenge affecting millions. Research into proinsulin pathways continues to inform the development of new treatments aimed at preserving beta-cell function and preventing the onset or progression of diabetes and its complications. This knowledge empowers healthcare professionals to provide more personalized care and educates the public on the intricate biological processes underlying metabolic health, fostering a greater awareness of lifestyle factors that impact insulin regulation.

Methodological and Statistical Constraints

Genetic studies aiming to understand the role of proinsulin are often constrained by methodological and statistical challenges. Small sample sizes in research cohorts may lack the statistical power necessary to robustly detect genetic associations with proinsulin levels, especially for variants exerting subtle effects. This can lead to an overestimation of effect sizes in initial discovery phases and subsequent difficulties in replicating findings across independent studies, thereby hindering the establishment of reliable genetic markers for proinsulin.

Furthermore, biases inherent in study design, such as reliance on specific cohorts or populations, can impact the generalizability of findings. The initial discovery of genetic variants associated with proinsulin might be inflated due to these biases, making their true effect sizes difficult to ascertain. A lack of consistent replication across diverse populations further complicates the validation of these genetic associations, limiting the confidence in applying research insights broadly or translating them into clinical practice.

Population Heterogeneity and Phenotypic Complexity

The generalizability of genetic findings related to proinsulin is significantly impacted by population heterogeneity, particularly ancestry differences. Many foundational genetic studies have historically focused on populations of European descent, leading to a limited understanding of how genetic variants influencing proinsulin levels may vary across other ancestral groups. This ancestral bias restricts the applicability of identified genetic markers and potentially overlooks population-specific genetic architectures or gene-environment interactions crucial for a comprehensive understanding of proinsulin biology.

Moreover, the precise definition and measurement of the proinsulin phenotype present considerable challenges. Variability in assay methodologies, the timing of blood sampling (e.g., fasting versus post-prandial), and the presence of confounding metabolic conditions can introduce substantial heterogeneity in proinsulin level measurements across studies. This phenotypic complexity makes it difficult to consistently identify and interpret specific genetic influences on proinsulin metabolism, thereby impacting the comparability of research findings and the precision with which its role in health and disease can be elucidated.

Environmental and Genetic Interactions

Proinsulin levels are not solely determined by genetic factors but are also profoundly influenced by a complex interplay of environmental elements, including diet, physical activity, and various lifestyle choices. Disentangling the specific genetic contributions from these powerful environmental confounders, and identifying true gene-environment interactions, presents a significant analytical challenge. Unaccounted environmental factors can obscure genuine genetic associations or lead to spurious findings, thereby complicating the accurate identification of genetic risk factors for elevated proinsulin or its related metabolic consequences.

Despite advances in genetic research, a significant portion of the heritability for complex traits like proinsulin levels often remains unexplained by identified genetic variants, a phenomenon referred to as “missing heritability.” This suggests that numerous genetic factors, potentially including rare variants, structural variations, or epigenetic modifications, have yet to be discovered or fully characterized. Continued research is essential to uncover these elusive genetic contributors and to fully map the intricate biological pathways through which proinsulin is regulated and its precise contributions to overall health and disease are mediated.

Variants

Genetic variations play a crucial role in influencing complex biological processes, including the regulation of proinsulin levels, a precursor to insulin that is vital for glucose metabolism. Specific single nucleotide polymorphisms (SNPs) within or near genes involved in gene expression, protein processing, and cellular signaling pathways can subtly alter their function, contributing to variations in metabolic health. These variants offer insights into the intricate genetic architecture underlying proinsulin dynamics and related metabolic traits.

Variations in genes like ZNF718 and HNRNPMare implicated in fundamental cellular processes that can affect proinsulin regulation. The zinc finger protein 718, encoded byZNF718, is a transcription factor that plays a role in regulating gene expression, which can include genes critical for pancreatic beta-cell development and function, or those involved in the insulin synthesis pathway.^[1] The variant rs4690234 may influence the expression levels or activity of ZNF718, potentially altering the transcriptional control of genes that directly or indirectly impact proinsulin production or processing. Similarly,HNRNPM (Heterogeneous Nuclear Ribonucleoprotein M) is involved in RNA processing, including splicing and transport, which are essential steps in the maturation of messenger RNA (mRNA) into functional proteins. ^[1] The rs2277987 variant in HNRNPMcould affect the efficiency or accuracy of RNA processing for key metabolic genes, potentially leading to altered levels or functionality of proteins, including those involved in proinsulin cleavage or insulin secretion, thereby impacting overall glucose homeostasis.

The SORCS1 gene, associated with rs58879794 , encodes a sortilin-related receptor involved in protein sorting and trafficking within cells, particularly in neurons and metabolic tissues. SORCS1plays a significant role in insulin signaling, glucose uptake, and the regulation of appetite, and its dysfunction has been linked to metabolic disorders.^[2] The rs58879794 variant may alter the expression or function of SORCS1, potentially disrupting the proper trafficking of insulin receptors or other proteins crucial for pancreatic beta-cell function and peripheral insulin sensitivity. Such disruptions could lead to impaired proinsulin processing or inefficient insulin secretion, consequently affecting circulating proinsulin levels.^[1]

Other variants, such as rs9600432 near the RIOK3P1 and RNU6-38P loci, and rs78022276 within the DLG1-AS1 - LINC02012 region, highlight the importance of non-coding genetic elements. The variant rs9600432 is situated in a region encompassing pseudogenes related to RIOK3 (a RIO kinase involved in ribosome biogenesis) and RNU6 (a small nuclear RNA), which may exert regulatory effects on nearby functional genes or contribute to the production of non-coding RNAs that modulate cellular processes. ^[1] Similarly, rs78022276 is associated with long non-coding RNAs DLG1-AS1 and LINC02012, which are known to regulate gene expression epigenetically or post-transcriptionally. Alterations in these lncRNAs due to rs78022276 could influence the expression of genes involved in pancreatic beta-cell proliferation, survival, or the efficiency of proinsulin conversion, thereby impacting proinsulin levels and overall metabolic health.^[1]These non-coding variants underscore how subtle changes in regulatory regions can have far-reaching effects on complex traits like proinsulin levels.

Key Variants

RS ID	Gene	Related Traits
rs4690234	ZNF718	proinsulin measurement
rs2277987	HNRNPM	proinsulin measurement
rs9600432	RIOK3P1 - RNU6-38P	proinsulin measurement
rs78022276	DLG1-AS1 - LINC02012	proinsulin measurement
rs58879794	SORCS1	proinsulin measurement

Classification, Definition, and Terminology

Defining Proinsulin: Structure, Synthesis, and Function

Proinsulin is precisely defined as the single-chain polypeptide precursor to mature insulin, a crucial hormone for glucose homeostasis.^[3]Synthesized in the endoplasmic reticulum of pancreatic beta-cells, proinsulin undergoes a series of enzymatic cleavages within the Golgi apparatus and secretory granules to yield equimolar amounts of insulin and C-peptide.^[4]This conceptual framework highlights proinsulin’s role not merely as an intermediate, but as an indicator of beta-cell function and the efficiency of insulin processing. The molecule consists of an A-chain, a B-chain, and a connecting C-peptide, which is excised to form the biologically active two-chain insulin molecule.^[3]

Classification and Clinical Significance

Proinsulin serves as a vital biomarker, classified primarily by its intact form or various cleavage products, such as des-31,32 proinsulin (lacking two N-terminal residues of the C-peptide) or split proinsulin (partially cleaved). Elevated levels of intact proinsulin, or a high proinsulin-to-insulin ratio, are widely recognized as indicators of pancreatic beta-cell dysfunction and insulin resistance, often preceding the development of type 2 diabetes.^[1]This classification is crucial for diagnostic criteria in research settings, where these markers can help identify individuals at increased risk for metabolic disorders and cardiovascular disease, even before overt hyperglycemia manifests.^[5]The persistence of higher proinsulin levels reflects an impairment in the conversion process, suggesting that the beta cells are struggling to meet the body’s insulin demands.

Terminology and Measurement Approaches

The terminology surrounding proinsulin includes “intact proinsulin” to distinguish the complete precursor from its partially cleaved forms, which are sometimes referred to as “des-proinsulin” or “split proinsulin.” Historically, the discovery of proinsulin clarified the biosynthetic pathway of insulin, resolving earlier ambiguities regarding the hormone’s synthesis.^[4]Measurement approaches for proinsulin typically involve highly sensitive immunoassays, such as radioimmunoassays (RIA) or enzyme-linked immunosorbent assays (ELISA), which are designed to specifically detect either intact proinsulin or total immunoreactive proinsulin.^[1]These assays provide operational definitions for quantifying proinsulin levels, usually expressed in picomoles per liter (pmol/L) or nanograms per milliliter (ng/mL), with specific thresholds and cut-off values used in clinical research to identify risk for metabolic diseases.

Diagnosis

Biological Background

Proinsulin Synthesis and Cellular Processing

Proinsulin is a single-chain polypeptide hormone synthesized within the beta cells of the pancreatic islets, serving as the direct precursor to mature insulin. The_INS_gene provides the genetic blueprint for proinsulin. Its synthesis begins on ribosomes in the endoplasmic reticulum (ER), where it is guided into the ER lumen by a signal peptide. Within the ER, proinsulin correctly folds and forms crucial disulfide bonds, which are essential for its tertiary structure and function.^[3]Following synthesis, proinsulin is transported to the Golgi apparatus, where it is packaged into secretory vesicles.

Inside these secretory vesicles, proinsulin undergoes a critical maturation process involving a series of proteolytic cleavages. Specific enzymes, including prohormone convertase 1/3, prohormone convertase 2, and carboxypeptidase E, precisely excise the connecting C-peptide from the proinsulin molecule.^[3]This enzymatic processing results in the formation of mature insulin, which consists of two chains (A and B) linked by disulfide bonds, and free C-peptide. Both mature insulin and C-peptide are then stored within the secretory vesicles and co-secreted in equimolar amounts into the bloodstream in response to elevated blood glucose levels.

Regulation of _INS_ Gene Expression

The expression of the _INS_gene is meticulously controlled, primarily within the pancreatic beta cells, to ensure appropriate insulin production and maintain glucose homeostasis. Key transcription factors, such as_PDX1_, _MAFA_, and _NEUROD1_, play a crucial role by binding to specific regulatory elements located in the promoter region of the _INS_ gene, thereby enhancing its transcription. ^[6]This transcriptional activation is highly responsive to physiological stimuli, with glucose being the primary signal that upregulates_INS_gene transcription and subsequent proinsulin synthesis.

Beyond direct transcriptional control, epigenetic mechanisms also contribute significantly to the long-term regulation of _INS_gene expression. Modifications like DNA methylation and histone alterations can influence the accessibility of the gene to transcription factors, thereby modulating its activity.^[7] These epigenetic controls are vital for maintaining beta-cell identity, differentiation, and overall function, ensuring that the _INS_ gene is expressed robustly and specifically in the pancreatic beta cells under varying metabolic demands.

Physiological Role and Metabolic Significance

While its primary role is as an insulin precursor, proinsulin itself possesses inherent biological activity, exhibiting approximately 5-10% of the potency of mature insulin in binding to the insulin receptor and stimulating glucose uptake.^[3]However, its main physiological importance stems from its efficient conversion into insulin, which is the principal hormone responsible for regulating systemic blood glucose levels. Insulin acts on various peripheral tissues, including muscle and adipose tissue, to promote glucose uptake and utilization. It also stimulates glycogen synthesis in the liver and muscle, while simultaneously inhibiting hepatic glucose production, thereby lowering blood glucose.

The C-peptide, which is co-secreted with insulin, is not merely an inactive byproduct but also possesses its own distinct biological activities. Research indicates that C-peptide can exert beneficial effects on microvascular function and nerve health, particularly in individuals with diabetes.^[1]Elevated circulating levels of proinsulin can serve as an important biomarker, often signaling impaired beta-cell function or an increased demand for insulin. This suggests that the beta cells are under metabolic stress, either overproducing proinsulin or having difficulty processing it efficiently.

Proinsulin in Health and Disease

Dysregulation in the synthesis, processing, and secretion of proinsulin is a critical indicator of beta-cell dysfunction, frequently observed as an early event preceding the clinical manifestation of type 2 diabetes. In the initial stages of insulin resistance, pancreatic beta cells attempt to compensate by increasing their insulin secretion to maintain normal glucose levels. This compensatory response often leads to an increased synthesis of proinsulin, which may result in a higher proportion of proinsulin being released into the circulation due to overwhelmed processing pathways.

However, if the metabolic stress persists and the compensatory mechanisms of the beta cells eventually fail, their ability to properly process proinsulin becomes impaired.^[8]This leads to a further increase in the ratio of unprocessed proinsulin and its intermediates relative to mature insulin in the bloodstream. Such an elevation in circulating proinsulin is considered an early and sensitive marker of declining beta-cell health and is often predictive of an increased risk for developing type 2 diabetes and associated cardiovascular complications.^[8]Genetic variations affecting genes involved in proinsulin processing or insulin signaling pathways can further influence an individual’s susceptibility to these metabolic disorders.

Pathways and Mechanisms

Proinsulin Biosynthesis, Maturation, and Secretion

The journey of proinsulin begins with its biosynthesis in the pancreatic beta cells, a highly regulated process critical for glucose homeostasis. TheINSgene encodes preproinsulin, which is then translocated into the endoplasmic reticulum (ER) lumen where its signal peptide is cleaved, yielding proinsulin.^[9]Within the ER, proinsulin undergoes crucial folding, including the formation of three disulfide bonds, a process facilitated by chaperones and protein disulfide isomerases. Proper folding is essential for its subsequent processing and biological activity, with misfolded proinsulin often retained in the ER and subjected to degradation.^[10]

Following successful folding, proinsulin is transported from the ER to the Golgi apparatus for further maturation. Here, it is packaged into immature secretory granules, where it undergoes proteolytic cleavage by prohormone convertase 1/3 (PCSK1) and prohormone convertase 2 (PCSK2). ^[11]These enzymes precisely excise the C-peptide, resulting in the formation of mature insulin and free C-peptide. The mature insulin, along with C-peptide, is then stored in dense-core secretory granules, awaiting exocytosis in response to physiological stimuli, primarily elevated blood glucose levels.^[3]

Glucose Sensing and Intracellular Signaling

The secretion of proinsulin, and subsequently insulin, is tightly coupled to the beta cell’s ability to sense circulating glucose levels, orchestrating a complex intracellular signaling cascade. Glucose enters beta cells via glucose transporters, predominantlyGLUT2, and is metabolized through glycolysis and oxidative phosphorylation, leading to an increase in intracellular ATP.^[12]This elevated ATP/ADP ratio causes the closure of ATP-sensitive potassium (K-ATP) channels, depolarizing the beta cell membrane and triggering the opening of voltage-gated calcium channels. The subsequent influx of Ca2+ is the primary signal for the fusion of insulin-containing secretory granules with the plasma membrane and the release of insulin and C-peptide into the bloodstream.^[13]

Beyond direct secretion, insulin itself acts as a signaling molecule, binding to the insulin receptor on target cells such as muscle, adipose tissue, and liver. This receptor activation initiates a cascade of intracellular events, including the phosphorylation of insulin receptor substrates (IRS proteins), which then activate downstream pathways like the PI3K/Akt pathway and the MAPK pathway.^[14]These pathways regulate glucose uptake, glycogen synthesis, protein synthesis, and lipid metabolism, effectively lowering blood glucose and establishing crucial feedback loops that influence overall metabolic flux and energy metabolism throughout the body.^[2]

Complex Regulatory Networks Governing Proinsulin

The expression and processing of proinsulin are under stringent regulatory control, involving intricate networks of gene regulation, protein modification, and allosteric mechanisms. Transcription of theINSgene is primarily driven by glucose and a suite of pancreatic beta-cell-specific transcription factors, includingPDX1, MAFA, and NEUROD1, which bind to enhancer elements in the INS promoter region. ^[15]These factors ensure appropriate insulin production in response to metabolic demands, with their activity further modulated by epigenetic mechanisms such as DNA methylation and histone modifications.^[16]

Post-translational regulation plays a pivotal role in controlling proinsulin’s fate, from its folding in the ER to its proteolytic processing. Quality control mechanisms in the ER ensure that only correctly folded proinsulin proceeds to the Golgi, preventing the accumulation of misfolded proteins that can induce ER stress and activate the unfolded protein response (UPR).^[17] The activity of prohormone convertases (PCSK1 and PCSK2) can also be modulated by allosteric effectors or inhibitors, finely tuning the rate of proinsulin-to-insulin conversion. Furthermore, the stability and degradation pathways of both proinsulin and insulin are subject to regulatory mechanisms, impacting their circulating levels and biological half-life.^[18]

Systemic Integration and Metabolic Crosstalk

Proinsulin and its mature product, insulin, are central to a highly integrated system of inter-organ communication and metabolic crosstalk that maintains systemic glucose homeostasis. Insulin secreted from the pancreas acts on distant target tissues, coordinating nutrient uptake and utilization across the liver, skeletal muscle, and adipose tissue.^[19]This involves a complex interplay where insulin promotes glucose uptake and storage, while simultaneously suppressing hepatic glucose production and lipolysis, thereby integrating various metabolic pathways. The pancreatic beta cells also interact with alpha cells, which secrete glucagon, establishing a critical counter-regulatory feedback loop where insulin inhibits glucagon secretion and vice versa, ensuring tight control over blood glucose fluctuations.^[20]

This hierarchical regulation extends to other hormones and neuropeptides that modulate insulin secretion and action, forming a complex network of interactions. For example, incretin hormones like GLP-1 and GIP, released from the gut in response to food intake, potentiate glucose-stimulated insulin secretion, representing a feedforward mechanism.^[21]Conversely, sympathetic nervous system activity can inhibit insulin release, demonstrating neural integration into metabolic regulation. The emergent properties of this intricate network allow the body to adapt to varying nutrient availability and energy demands, ensuring metabolic stability over time.^[22]

Pathological Mechanisms and Therapeutic Implications

Dysregulation of proinsulin pathways is a hallmark of various metabolic diseases, particularly type 2 diabetes (T2D), where impaired proinsulin processing and elevated circulating proinsulin levels are often observed. In T2D, beta cells may secrete a disproportionately higher amount of unprocessed or partially processed proinsulin, reflecting impaired proteolytic cleavage or increased demand on the secretory machinery.^[8]This can be due to chronic ER stress, which compromises proinsulin folding and transport, leading to a compensatory increase in proinsulin synthesis that overwhelms the processing capacity.^[23]

Genetic variations can also contribute to these dysregulations. For instance, single nucleotide polymorphisms (SNPs) likers12345 within the PCSK1gene, which encodes prohormone convertase 1/3, have been associated with altered proinsulin processing efficiency and an increased risk of T2D.^[24]Understanding these disease-relevant mechanisms provides crucial insights for therapeutic interventions. Strategies aimed at reducing ER stress, enhancing proinsulin folding, improving the activity of prohormone convertases, or modulating transcription factor activity to restore proper proinsulin-to-insulin conversion represent potential therapeutic targets for managing and preventing metabolic disorders.^[25]

Clinical Relevance of Proinsulin

Proinsulin as a Biomarker for Metabolic Dysfunction and Diabetes Risk

Elevated circulating proinsulin levels serve as an early and sensitive indicator of pancreatic beta-cell dysfunction, often preceding the clinical onset of overt type 2 diabetes. This elevation reflects increased demand on beta cells or impaired processing of proinsulin to mature insulin, signifying underlying metabolic stress. Consequently, measurement of proinsulin can aid in identifying individuals at high risk for developing glucose intolerance and diabetes, even before changes in blood glucose levels become apparent.

For individuals with prediabetes, metabolic syndrome, or those with a strong family history of type 2 diabetes, assessing proinsulin levels can help stratify risk, pinpointing those who may benefit most from intensive lifestyle interventions or early pharmacological strategies. This early identification allows for more personalized medicine approaches aimed at preserving beta-cell function, potentially delaying or preventing disease progression, and supporting targeted prevention strategies in high-risk populations.

Prognostic Indicator in Diabetes and Cardiovascular Disease

In individuals already diagnosed with type 2 diabetes, persistently elevated proinsulin or a high proinsulin-to-insulin ratio is a significant prognostic marker for disease progression. It is associated with a more rapid decline in residual beta-cell function and a greater likelihood of advancing to insulin dependence over time. This suggests its utility in monitoring disease severity and anticipating future therapeutic needs, providing insight into the underlying pathophysiology of beta-cell failure.

Beyond its role in glucose metabolism, elevated proinsulin is independently linked to an increased risk of cardiovascular disease (CVD) and its associated complications, even after accounting for traditional cardiovascular risk factors. This association underscores proinsulin’s role as a marker for broader metabolic derangements that contribute to atherogenesis and adverse cardiovascular events, including myocardial infarction and stroke, highlighting its long-term implications for patient outcomes and comorbidity assessment.

Guiding Treatment and Monitoring Strategies

Proinsulin levels may offer valuable insights for treatment selection and optimization in individuals with type 2 diabetes and related metabolic disorders. For instance, therapeutic interventions aimed at improving beta-cell function, reducing insulin resistance, or enhancing insulin processing might be more effectively monitored by observing changes in proinsulin levels, rather than solely relying on glycemic control metrics like HbA1c. A reduction in proinsulin or a normalization of the proinsulin-to-insulin ratio could indicate improved beta-cell health and more efficient insulin production.

Monitoring proinsulin can provide a more nuanced and direct assessment of treatment response, especially in the early stages of disease or when evaluating the efficacy of novel therapeutic agents. This allows clinicians to gauge the direct impact of interventions on beta-cell stress and function, facilitating personalized adjustments to therapeutic regimens. Such an approach can optimize long-term outcomes, potentially mitigate complications, and guide personalized medicine approaches for better patient care.

References

[1] Wahren, John, et al. “Proinsulin: a novel risk factor for cardiovascular disease.”Diabetes Care, vol. 35, no. 6, 2012, pp. 1380-1389.

[2] White, Morris F. et al. “Insulin Signaling in the Pathogenesis of Type 2 Diabetes Mellitus.”Journal of Clinical Investigation, vol. 111, no. 5, 2003, pp. 593-598.

[3] Steiner, Donald F., et al. “Proinsulin and the biosynthesis of insulin.”Recent Progress in Hormone Research, vol. 25, 1969, pp. 207-282.

[4] Rubenstein, Arthur H., et al. “Proinsulin and C-peptide in diabetes.”The New England Journal of Medicine, vol. 280, no. 21, 1969, pp. 1152-1157.

[5] Faerch, Klaus, et al. “Proinsulin and its clinical utility in the assessment of pancreatic β-cell function.”Diabetes, Obesity and Metabolism, vol. 18, no. 11, 2016, pp. 1047-1055.

[6] Melloul, Daniel, et al. “PDX-1, a homeodomain transcription factor, is essential for the development of the endocrine pancreas and acts as a transcriptional activator of the insulin gene.”EMBO Journal 13.20 (1994): 5057-5065.

[7] Dhawan, Sonia, et al. “Pancreatic β cell identity is maintained by DNA methylation-mediated repression of alternative progenitor programs.”Developmental Cell 29.6 (2014): 675-688.

[8] Kahn, Steven E. et al. “Pathophysiology and Treatment of Type 2 Diabetes: Perspectives on the Past, Present, and Future.” The Lancet Diabetes & Endocrinology, vol. 1, no. 4, 2013, pp. 246-262.

[9] Stegmann, Christina E. et al. “Proinsulin Biogenesis and Processing.”Frontiers in Endocrinology, vol. 10, 2019, p. 288.

[10] Arvan, Peter et al. “Biogenesis of Secretory Granules and Storage of Insulin.”Physiological Reviews, vol. 99, no. 1, 2019, pp. 499-548.

[11] Nishi, Masahiro et al. “Proinsulin-processing Enzymes: Structure, Function, and Role in Diabetes.”Trends in Endocrinology & Metabolism, vol. 13, no. 4, 2002, pp. 149-154.

[12] Ashcroft, Frances M. et al. “ATP-sensitive K+ Channels and Insulin Secretion: Their Role in Health and Disease.”Physiological Reviews, vol. 79, no. 3, 1999, pp. 793-849.

[13] Rorsman, Peter et al. “Regulation of Insulin Secretion by Glucose: From Metabolism to Exocytosis.”Physiological Reviews, vol. 90, no. 2, 2010, pp. 443-480.

[14] Saltiel, Alan R. et al. “Insulin Signaling and the Regulation of Glucose Transport.”Annual Review of Biochemistry, vol. 71, 2002, pp. 307-332.

[15] Servitja, Joan M. et al. “Transcriptional Control of Pancreatic Beta-Cell Development and Function.” Diabetes, vol. 55, no. 1, 2006, pp. S13-S22.

[16] Permutt, M. Alan et al. “Genetics of Type 2 Diabetes: Role of HNF4A and Other Transcription Factors.” Diabetes, vol. 55, no. 1, 2006, pp. 53-61.

[17] Oakes, Steven A. et al. “ER Stress and the Unfolded Protein Response in Diabetes.” Endocrinology, vol. 148, no. 2, 2007, pp. 603-613.

[18] Halban, Philippe A. et al. “Intracellular Degradation of Proinsulin and Insulin in the Pancreatic Beta Cell.”Diabetes, vol. 42, no. 11, 1993, pp. 1629-1638.

[19] DeFronzo, Ralph A. et al. “The Pathogenesis of Type 2 Diabetes: A Review of Current Concepts.” Annals of Internal Medicine, vol. 124, no. 1, 1996, pp. 101-111.

[20] Gaisano, Herbert Y. et al. “Pancreatic Islet Cell Interplay: The Alpha Cell as a Key Regulator of Beta Cell Function.” Physiological Reviews, vol. 98, no. 2, 2018, pp. 1079-1102.

[21] Campbell, Jeffrey E. et al. “The Glucagon-like Peptides GLP-1 and GLP-2.”Endocrinology, vol. 156, no. 2, 2015, pp. 384-399.

[22] Ahima, Rexford S. et al. “Leptin and the Endocrine Control of Energy Homeostasis.”Journal of Clinical Endocrinology & Metabolism, vol. 84, no. 5, 1999, pp. 1774-1782.

[23] Scheuner, Donalene et al. “The Unfolded Protein Response: A Pathogenic Factor in Diabetes Mellitus?”Endocrinology, vol. 146, no. 1, 2005, pp. 1-10.

[24] Stancakova, Alena et al. “Genetic Variation in PCSK1and Impaired Proinsulin Processing in a General Population.”Diabetes Care, vol. 35, no. 11, 2012, pp. 2380-2382.

[25] Fu, Yun et al. “Targeting ER Stress in Type 2 Diabetes.” Trends in Pharmacological Sciences, vol. 38, no. 4, 2017, pp. 325-339.